Actos

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
28-08-2023
产品特点 产品特点 (SPC)
28-08-2023
公众评估报告 公众评估报告 (PAR)
29-09-2016

有效成分:

pioglitazone hydrochloride

可用日期:

CHEPLAPHARM Arzneimittel GmbH

ATC代码:

A10BG03

INN(国际名称):

pioglitazone

治疗组:

Drugs used in diabetes

治疗领域:

Diabetes Mellitus, Type 2

疗效迹象:

Pioglitazone is indicated in the treatment of type-2 diabetes mellitus:as monotherapy:in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.Pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.

產品總結:

Revision: 30

授权状态:

Authorised

授权日期:

2000-10-13

资料单张

                                28
B. PACKAGE LEAFLET
29
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
ACTOS 15 MG TABLETS
ACTOS 30 MG TABLETS
ACTOS 45 MG TABLETS
pioglitazone
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Actos is and what it is used for
2.
What you need to know before you take Actos
3.
How to take Actos
4.
Possible side effects
5.
How to store Actos
6.
Contents of the pack and other information
1.
WHAT ACTOS IS AND WHAT IT IS USED FOR
Actos contains pioglitazone. It is an anti-diabetic medicine used to
treat type 2 (non-insulin dependent)
diabetes mellitus in adults, when metformin is not suitable or has
failed to work adequately. This is the
diabetes that usually develops in adulthood.
Actos helps control the level of sugar in your blood when you have
type 2 diabetes by helping your
body make better use of the insulin it produces. Your doctor will
check whether Actos is working 3 to
6 months after you start taking it.
Actos may be used on its own in patients who are unable to take
metformin, and where treatment with
diet and exercise has failed to control blood sugar or may be added to
other therapies (such as
metformin, sulphonylurea or insulin) which have failed to provide
sufficient control of blood sugar.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ACTOS
DO NOT TAKE ACTOS
-
if you are allergic to pioglitazone or any of the other ingredients of
this medicine (listed in
section 6).
-
if you have heart failure or have had heart failure in the past.
-
if you have liver disease.
-
if you have had diabetic ketoa
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Actos 15 mg tablets
Actos 30 mg tablets
Actos 45 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Actos 15 mg tablets
Each tablet contains 15 mg of pioglitazone (as hydrochloride).
_Excipient with known effect_
Each tablet contains 92.87 mg of lactose monohydrate (see section
4.4).
Actos 30 mg tablets
Each tablet contains 30 mg of pioglitazone (as hydrochloride).
_Excipient with known effect_
Each tablet contains 76.34 mg of lactose monohydrate (see section
4.4).
Actos 45 mg tablets
Each tablet contains 45 mg of pioglitazone (as hydrochloride).
_Excipient with known effect_
Each tablet contains 114.51 mg of lactose monohydrate (see section
4.4).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Actos 15 mg tablets
The tablets are white to off-white, round, convex and marked ‘15’
on one face and ‘ACTOS’ on the
other face.
Actos 30 mg tablets
The tablets are white to off-white, round, flat and marked ‘30’ on
one face and ‘ACTOS’ on the other
face.
Actos 45 mg tablets
The tablets are white to off-white, round, flat and marked ‘45’ on
one face and ‘ACTOS’ on the other
face.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Pioglitazone is indicated as second or third line treatment of type 2
diabetes mellitus as described
below:
3
as
MONOTHERAPY
-
in adult patients (particularly overweight patients) inadequately
controlled by diet and
exercise for whom metformin is inappropriate because of
contraindications or
intolerance
as
DUAL ORAL THERAPY
in combination with
-
metformin, in adult patients (particularly overweight patients) with
insufficient
glycaemic control despite maximal tolerated dose of monotherapy with
metformin
-
a sulphonylurea, only in adult patients who show intolerance to
metformin or for
whom metformin is contraindicated, with insufficient glycaemic control
despite
maximal tolerated dose of monotherapy with a sulphonylurea.
as
TRIPLE ORAL THERAPY
in combination 
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 28-08-2023
产品特点 产品特点 保加利亚文 28-08-2023
公众评估报告 公众评估报告 保加利亚文 29-09-2016
资料单张 资料单张 西班牙文 28-08-2023
产品特点 产品特点 西班牙文 28-08-2023
公众评估报告 公众评估报告 西班牙文 29-09-2016
资料单张 资料单张 捷克文 28-08-2023
产品特点 产品特点 捷克文 28-08-2023
公众评估报告 公众评估报告 捷克文 29-09-2016
资料单张 资料单张 丹麦文 28-08-2023
产品特点 产品特点 丹麦文 28-08-2023
公众评估报告 公众评估报告 丹麦文 29-09-2016
资料单张 资料单张 德文 28-08-2023
产品特点 产品特点 德文 28-08-2023
公众评估报告 公众评估报告 德文 29-09-2016
资料单张 资料单张 爱沙尼亚文 28-08-2023
产品特点 产品特点 爱沙尼亚文 28-08-2023
公众评估报告 公众评估报告 爱沙尼亚文 29-09-2016
资料单张 资料单张 希腊文 28-08-2023
产品特点 产品特点 希腊文 28-08-2023
公众评估报告 公众评估报告 希腊文 29-09-2016
资料单张 资料单张 法文 28-08-2023
产品特点 产品特点 法文 28-08-2023
公众评估报告 公众评估报告 法文 29-09-2016
资料单张 资料单张 意大利文 28-08-2023
产品特点 产品特点 意大利文 28-08-2023
公众评估报告 公众评估报告 意大利文 29-09-2016
资料单张 资料单张 拉脱维亚文 28-08-2023
产品特点 产品特点 拉脱维亚文 28-08-2023
公众评估报告 公众评估报告 拉脱维亚文 29-09-2016
资料单张 资料单张 立陶宛文 28-08-2023
产品特点 产品特点 立陶宛文 28-08-2023
公众评估报告 公众评估报告 立陶宛文 29-09-2016
资料单张 资料单张 匈牙利文 28-08-2023
产品特点 产品特点 匈牙利文 28-08-2023
公众评估报告 公众评估报告 匈牙利文 29-09-2016
资料单张 资料单张 马耳他文 28-08-2023
产品特点 产品特点 马耳他文 28-08-2023
公众评估报告 公众评估报告 马耳他文 29-09-2016
资料单张 资料单张 荷兰文 28-08-2023
产品特点 产品特点 荷兰文 28-08-2023
公众评估报告 公众评估报告 荷兰文 29-09-2016
资料单张 资料单张 波兰文 28-08-2023
产品特点 产品特点 波兰文 28-08-2023
公众评估报告 公众评估报告 波兰文 29-09-2016
资料单张 资料单张 葡萄牙文 28-08-2023
产品特点 产品特点 葡萄牙文 28-08-2023
公众评估报告 公众评估报告 葡萄牙文 29-09-2016
资料单张 资料单张 罗马尼亚文 28-08-2023
产品特点 产品特点 罗马尼亚文 28-08-2023
公众评估报告 公众评估报告 罗马尼亚文 29-09-2016
资料单张 资料单张 斯洛伐克文 28-08-2023
产品特点 产品特点 斯洛伐克文 28-08-2023
公众评估报告 公众评估报告 斯洛伐克文 29-09-2016
资料单张 资料单张 斯洛文尼亚文 28-08-2023
产品特点 产品特点 斯洛文尼亚文 28-08-2023
公众评估报告 公众评估报告 斯洛文尼亚文 29-09-2016
资料单张 资料单张 芬兰文 28-08-2023
产品特点 产品特点 芬兰文 28-08-2023
公众评估报告 公众评估报告 芬兰文 29-09-2016
资料单张 资料单张 瑞典文 28-08-2023
产品特点 产品特点 瑞典文 28-08-2023
公众评估报告 公众评估报告 瑞典文 29-09-2016
资料单张 资料单张 挪威文 28-08-2023
产品特点 产品特点 挪威文 28-08-2023
资料单张 资料单张 冰岛文 28-08-2023
产品特点 产品特点 冰岛文 28-08-2023
资料单张 资料单张 克罗地亚文 28-08-2023
产品特点 产品特点 克罗地亚文 28-08-2023
公众评估报告 公众评估报告 克罗地亚文 29-09-2016

搜索与此产品相关的警报

查看文件历史